Clinical study on 10 cases of pancytopenia selectively treated by cyclosporine a.
- Author:
Hong-Xia QIU
1
;
Jian-Yong LI
;
Ji XU
;
Xin LV
;
Wei XU
;
Su-Jiang ZHANG
;
Han-Xing WU
;
Jing-Zhang SHAO
Author Information
1. Department of Hematology, The First Hospital, Nanjing Medical University, Jiangsu Provincial People Hospital, Nanjing 210029, Jiangsu Province, China.
- Publication Type:Clinical Trial
- MeSH:
Adolescent;
Adult;
Cyclosporine;
therapeutic use;
Female;
Humans;
Immunosuppressive Agents;
therapeutic use;
Male;
Middle Aged;
Pancytopenia;
drug therapy;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2009;17(4):1047-1051
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to explore the effect and adverse reaction of cyclosporine A (CsA) in treatment of pancytopenia without reticulocyte decrease but with elevated LDH. 10 patients were selected according to our standards and were treated by CsA. The curative effect and adverse reaction of patients were evaluated by following up for 6 - 116 months. The effect of CsA in the maintenance treatment of AA patient with an obvious rise of LDH was illustrated by means of typical case. The results indicated that 10 patients had different diagnosis, but had similar clinical and laboratory characteristics. Among them, 9 patients showed a relatively good curative reaction to CsA. Treatment of 1 patient was stopped because of pneumonia tuberculosis. It is concluded that the elevated LDH without reticuleocyte decrease may be a biomarker to predict the curative reaction to CsA for patients with pancytopenia. Selectively treating pancytopenia with CsA can obtain a higher curative reaction and maintenance treatment with CsA is an important factor for reducing recurrence of this disease.
